Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977872 | 0.89 | PDE3A (0.63) | PDE3APDE10APDGFRBPDGFRAAURKA | |
| SCHEMBL2918088 | 0.78 | TLR9 (0.76) | PDGFRBPDGFRAAURKAACHEBACE1 | |
| SCHEMBL906243 | 0.76 | KIT (0.59) | PDE3APDGFRBPDGFRAAURKAACHE | |
| SCHEMBL5243679 | 0.75 | PDE3A (0.68) | PDE3APDE10AACHEBACE1HTR1A | |
| SCHEMBL5241625 | 0.75 | PDE3A (0.68) | PDE3APDE10AACHEBACE1HTR1A | |
| SCHEMBL5241619 | 0.75 | PDE3A (0.68) | PDE3APDE10AACHEBACE1HTR1A | |
| SCHEMBL5241633 | 0.75 | PDE3A (0.68) | PDE3APDE10AACHEBACE1HTR1A | |
| SCHEMBL5243694 | 0.75 | PDE3A (0.68) | PDE3APDE10AACHEBACE1HTR1A | |
| SCHEMBL23726903 | 0.75 | ACHE (0.67) | PDGFRBPDGFRAAURKAACHEBACE1 | |
| SCHEMBL23726611 | 0.75 | TLR9 (0.71) | PDGFRBPDGFRAAURKAACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994021-A2 | QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007103370-A2 | QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE5A, PDE7A | PDE3A 6/4885PDE10A 5/4885PDGFRB 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.